TruBridge (TBRG) Earnings Date & Reports

For the fourth quarter ended December 31, 2025, TruBridge posted total revenue of $87.2 million, down slightly from $88.1 million in the prior-year period and marginally below consensus expectations of approximately $87.6 million. Financial and patient care segments showed resilience, with Financial Health revenue up 2% to $56.2 million. Recurring revenue remained strong at 94% of the total.

On the bottom line, GAAP net loss widened modestly to $5.5 million, or $(0.37) per diluted share, compared to a $5.1 million loss last year. However, non-GAAP net income surged to $11.4 million, or $0.79 per diluted share, beating analyst consensus of $0.41 by a wide margin. Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) climbed 7% to $19.2 million, or 22% of revenue, reflecting 160 basis points of margin expansion from effective cost management.

Bookings totaled $19.8 million, a 39% increase YoY, fueled by $2.8 million in net new business and $8.9 million in cross-sells. For the full year, revenue rose 1.4% to $346.8 million, GAAP net income flipped to $4.4 million from a prior-year loss, and Adjusted EBITDA grew 23% to $68.7 million. No specific numerical guidance was issued for 2026, but management emphasized fundamentals and AI-driven enhancements.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your research process.

Market Reaction and Investor Sentiment

Following the March 31 after-market release, TruBridge shares exhibited a muted initial reaction, trading around $22.88 the next day amid focus on the GAAP loss and slight revenue miss. However, attention shifted to the adjusted metrics beat, robust bookings, and full-year profitability turnaround, supporting a recovery toward $25.77 by late April near the 52-week high of $26.74. Analysts responded positively, with BMO Capital raising its price target to $26.25 on April 24. Investor sentiment remains cautiously optimistic, balancing operational gains against the ongoing strategic review.

Forward Outlook and Key Factors to Monitor

TruBridge enters 2026 with momentum from improved earnings quality and a healthier bookings pipeline. Management anticipates modest revenue growth alongside approximately 200 basis points of Adjusted EBITDA margin expansion, driven by continued cost discipline and offshoring benefits.

Key priorities include a targeted AI initiative to modernize technology infrastructure, enhance offerings, and boost customer satisfaction. Investors should watch progress on customer metrics and retention, as recurring revenue stability is core to the model.

The strategic review process, evaluating options like potential sales, joint ventures, or share repurchases, represents a major catalyst. Updates will come only as required, but outcomes could significantly impact valuation. Broader healthcare RCM dynamics, such as payer mix shifts and reimbursement pressures, will also influence demand signals.

Upcoming catalysts include Q1 2026 results expected in early May and any 10-Q insights into margin trends or bookings quality.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations